Akira Watanabe
- Epidemiology top 5%
- Pneumonia and Respiratory Infections 31
- Influenza Virus Research Studies 12
- Respiratory viral infections research 11
- Mycobacterium research and diagnosis 6
- Molecular Medicine top 10%
- Antibiotic Resistance in Bacteria 8
- Infectious Diseases top 10%
- Tuberculosis Research and Epidemiology 7
-
- Antibiotics Pharmacokinetics and Efficacy 24
-
- Antibiotic Use and Resistance 6
Akira Watanabe
102 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 111
- Epidemiology 539
- Critical Care and Intensive Care Medicine 67
- Molecular Medicine 49
- Infectious Diseases 161
- Immunology 150
Countries citing papers authored by Akira Watanabe
This map shows the geographic impact of Akira Watanabe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akira Watanabe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akira Watanabe more than expected).
Fields of papers citing papers by Akira Watanabe
This network shows the impact of papers produced by Akira Watanabe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akira Watanabe. The network helps show where Akira Watanabe may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Akira Watanabe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2022 | 1 | |
| 3 | Multicenter open-label study of tazobactam/piperacillin in patients with hospital-acquired pneumonia | 2010 | 2 |
| 4 | Susceptibility to arbekacin of clinical strains of Pseudomonas aeruginosa isolated in the Tohoku area between 2003 and 2007 | 2009 | 2 |
| 5 | 2007 | 1 | |
| 6 | A dose-finding study on doripenem in chronic respiratory tract infection | 2005 | 1 |
| 7 | Comparative study of doripenem and meropenem in respiratory infections. Phase III double-blind comparative study | 2005 | 3 |
| 8 | Sepsis caused by methicillin-resistant Staphylococcus aureus (MRSA) without effects of vancomycin (VCM), teicoplanin (TEIC) and arbekacin (ABK) treated successfully and safely with intravenous administration of linezolid (LZD) | 2004 | 1 |
| 9 | Dose-finding study on telithromycin in bacterial pneumonia | 2003 | 1 |
| 10 | Clinical evaluation of telithromycin for community-acquired pneumonia - Phase III double-blind comparative study of telithromycin versus levofloxacin | 2003 | 1 |
| 11 | Rate of occurrence of mutations at Ser-84 in Staphylococcus aureus DNA gyrase A protein | 1995 | 2 |
| 12 | Studies on multiple-resistant staphylococcus aureus. (IV). Difference in incidence of methicillin-resistant staphylococcus aureus (MRSA) among institutions, departments and specimens | 1989 | 1 |
| 13 | 1989 | 1 | |
| 14 | 1988 | 2 | |
| 15 | 1986 | 1 | |
| 16 | 1983 | 0 | |
| 17 | 1982 | 1 | |
| 18 | 1980 | 1 | |
| 19 | 1980 | 1 | |
| 20 | 1967 | 1 |
About Akira Watanabe
Akira Watanabe is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine and Pharmacology, having authored 115 papers that have together received 1.1k indexed citations. Recurring topics across this work include Pneumonia and Respiratory Infections (31 papers), Antibiotics Pharmacokinetics and Efficacy (24 papers), Influenza Virus Research Studies (12 papers), Respiratory viral infections research (11 papers), Antibiotic Resistance in Bacteria (8 papers), Tuberculosis Research and Epidemiology (7 papers), Mycobacterium research and diagnosis (6 papers) and Antibiotic Use and Resistance (6 papers). The work is most often cited by research in Epidemiology (539 citations), Critical Care and Intensive Care Medicine (67 citations) and Molecular Medicine (49 citations). Akira Watanabe has collaborated with scholars based in Japan, United States and France. Frequent co-authors include Shan‐Chwen Chang, Yasuo Ohashi, Min Ja Kim, Seizaburo Kashiwagi, Tôru Ishibashi, Takeki Uehara, Nobuo Hirotsu, Kenji J. Tsuchiya, Takao Shishido and Shinya Omoto. Their work appears in journals such as Chemotherapy, Immunological Investigations, The Journal of Dermatology, Clinical Infectious Diseases and Modern Rheumatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.